ArQule Message Board - Msg: 1563874

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ArQule

ARQL 20.00

0.0%

Jan 16 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Czechsinthemail who wrote (63)	6/10/1997 10:31:00 AM
From: Dr. John M. de Castro	of 399

ARQL announced another collaboration this morning. This time it's with Fibrogen looking for therapeutics to reduce surgical scarring. prnewswire.com They have quite a set of collaborations and shared ownership rights to the discovered molecules in all of them. As the molecules from these collaborations come out of research into preclinical development, ARQL will have an amazing pipeline. John de C

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next